Evidence map›Paper›PMID 31286353›Full record

ArticleMolecular imaging and biology2020

Lactoferrin Protects Hyperoxia-Induced Lung and Kidney Systemic Inflammation in an In Vivo Imaging Model of NF-κB/Luciferase Transgenic Mice.

Chih-Ching Yen, Wen-Hui Chang, Min-Che Tung, Hsiao-Ling Chen, Hsu-Chung Liu, Chun-Huei Liao, Ying-Wei Lan, Kowit-Yu Chong, Shang-Hsun Yang, Chuan-Mu Chen

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Kidney protective potential of lactoferrin: pharmacological insights and therapeutic advances.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2022
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Chih-Ching Yen *Department of Life Sciences, National Chung Hsing University, Taichung, 402, Taiwan.
Wen-Hui Chang *Department of Life Sciences, National Chung Hsing University, Taichung, 402, Taiwan.
Min-Che Tung *Department of Surgery, Tungs' Taichung Metro Harbor Hospital, Taichung, 435, Taiwan.
Hsiao-Ling Chen *Department of Bioresources, Da-Yeh University, Changhua, 515, Taiwan.
Hsu-Chung LiuDepartment of Life Sciences, National Chung Hsing University, Taichung, 402, Taiwan.
Chun-Huei LiaoDepartment of Life Sciences, National Chung Hsing University, Taichung, 402, Taiwan.
Ying-Wei LanDepartment of Life Sciences, National Chung Hsing University, Taichung, 402, Taiwan.
Kowit-Yu ChongDepartment of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Tao-Yuan, 333, Taiwan.
Shang-Hsun YangDepartment of Physiology, and Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, 701, Taiwan.
Chuan-Mu ChenDepartment of Life Sciences, National Chung Hsing University, Taichung, 402, Taiwan. chchen1@dragon.nchu.edu.tw.ORCID http://orcid.org/0000-0003-2461-9150
National Chung Hsing University · TWChang Gung University · TWDayeh University · TWNational Cheng Kung University · TWTungs' Taichung MetroHarbor Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHigh levels of oxygen are usually used in ventilatory support and extracorporeal membrane oxygenation (ECMO) in the intensive care unit of hospitals. Hyperoxia may induce the production of reactive oxygen species (ROS) that can cause lung damage and even systemic injury. In this study, the NF-κB/luciferase transgenic mouse model with non-invasive real-time in vivo imaging was established to test the functions of lactoferrin (LF) in antioxidant and anti-inflammation. PROCEDURES: The NF-κB/luciferase transgenic mice were used to assess the effects of oral administration of LF on attenuation of the systemic inflammatory response and organ damage after 72 h of hyperoxia (FiO

resultsUsing luciferase IVIS imaging, we found that the lungs and kidneys were the most evidently affected organs after hyperoxia treatment. The groups treated with low dose (150 mg/kg) or high dose (300 mg/kg) of LF had lower luciferase expression and less injury, with a dose-dependent effect on the lungs and kidneys. Moreover, ROS, mitogen-activated protein kinases (MAPK), and pro-inflammatory cytokine (TNF-α, IL-1ß, and IL-6) expression levels were all significantly decreased (P < 0.01), and the protein level of IκB was statistically increased (P < 0.01) after LF treatment.

conclusionsOur results suggest that hyperoxia can induce systemic inflammation, and the oral administration of LF as a natural antioxidant decreases the production of ROS, attenuates inflammation, and lessens kidney and lung injuries from hyperoxia via the use of live image monitoring of the response in NF-kB/luciferase transgenic mice.

Indexed as

AnimalsAnti-Infective AgentsDisease Models, AnimalFemaleHyperoxiaKidney DiseasesLactoferrinLuciferasesMaleMiceMice, TransgenicNF-kappa BOxygen ConsumptionPneumoniaReactive Oxygen SpeciesAnti-Infective AgentsLactoferrinLuciferasesNF-kappa BReactive Oxygen SpeciesInflammatory cytokinesLactoferrin (LF)Live imagingNF-κB/luciferase transgenic miceReactive oxygen species (ROS)

Identifiers

PMID31286353
OpenAlexW2956407574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.